【摘要】 目的:研究厄贝沙坦预防房颤复律后复发的效果及治疗前后左房径的变化。方法:选取2004年5月至2005年12月我院住院治疗的应用胺碘酮转复为窦性心律的房颤患者100例,随机分为具有可比性的试验组(n=60)和对照组(n=40),两组患者在常规抗凝的基础上均给予口服胺碘酮治疗,逐渐减为维持量,0.2g/次,1次/d。试验组同时加用厄贝沙坦75-150mg/次,1次/d。对照组不给予血管紧张素转换酶抑制剂(ACE-I)类及血管紧张素受体拮抗剂(ARB)。观测终点为房颤复发或满12个月。结果:试验组房颤复发率低于对照组(23.33%比47.5%,p<0.05);治疗前后左房径无显著差异。结论:厄贝沙坦对房颤复律后复发有预防作用,尤其对心房电重构起到主导作用。更多还原

【Abstract】 Objective:To explore the effects of erbesartan used with low dose of amiodaron on the Recurrence after defibrillation and To analysis the change of left atrial diameter.Method: We recruited 100 patients with fibrillation in our hospital from May 2004 to Jun 2005.After defibrillation by amiodaron,these patients were randomly divided into comparable intervention group(n=60)and control group(n=40).Then patients in two groups were treated by 0.2g qd of amiodaron and anticoagulant.75～150 mg/day of Irbesartan was used in intervention patients,but not in control group.Not any ACE-I or ARB were used in control group.Research endpoint was recurrence of fibrillation or not in 12 months.Result:Recurrence rate were 23.33% and 47.50%(p<0.05) for intervention and control groups,respectively.There was no significant difference with left atrial diameter between the two groups.Conclusion: There was preventive effects of Irbesartan used on the recrudescent after defibrillation.Atrial electrical remodeling has leading function in the recurrence.更多还原